The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment ... The approval is based on the RUBY trial, which showed that Jemperli (dostarlimab) given with carboplatin and paclitaxel ...

GSK's latecomer to the PD-1/PD-L1 inhibitor ... and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda (pembrolizumab), showing it ...

PLYMOUTH, Mass., January 13, 2025--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...

Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...

In short, the GSK share price has disappointed shareholders for years. I know, as I have a tiny holding in this business, while my wife has a more meaningful stake. For decades, GSK was my family ...

Teva Pharmaceutical Industries Ltd. ADR-0.93% $19.32B ...

GlaxoSmithKline Pharmaceuticals shares hit 20 per cent upper circuit in trade on BSE at Rs 2,421.3 per share. The buying on the counter came after the company posted its Q3 results. Around 9:52 AM, ...